Primary biliary cholangitis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead t...
Comprehensive, easy-to-understand information about this condition
How we create this content →Connect with organizations supporting the primary biliary cholangitis community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Connect with organizations supporting the primary biliary cholangitis community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Connect with organizations supporting the primary biliary cholangitis community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
2 peer-reviewed sources from PubMed
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning primary biliary cholangitis
Updated Feb 19, 2026
A systematic review highlights the comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis. The findings suggest greater transplant-free survival with obeticholic acid in clinical trials compared to real-world controls.
A recent publication addresses the ethical considerations surrounding the use of unlicensed therapies in primary biliary cholangitis. This counter view contributes to the ongoing debate about treatment options for this rare liver disease.
A recent publication discusses the ethical considerations surrounding the use of unlicensed therapies in treating primary biliary cholangitis. The article presents a counter view on the implications of such practices in clinical settings.
Recent research highlights the efficacy of seladelpar in treating primary biliary cholangitis through selective PPAR δ activation. This study may pave the way for further applications of seladelpar in related conditions.